Tengonermin
Tengonermin, also known as TNF-beta or Lymphotoxin-alpha, is a cytokine that plays a crucial role in the immune system. It is a member of the tumor necrosis factor (TNF) superfamily, which is involved in inflammation and the regulation of immune cells.
Structure and Function[edit | edit source]
Tengonermin is a protein that is structurally similar to tumor necrosis factor alpha (TNF-alpha). It is produced by activated lymphocytes, particularly T cells and B cells. The protein functions as a homotrimer, meaning it forms a complex of three identical subunits.
Tengonermin binds to specific receptors on the surface of target cells, primarily the lymphotoxin-beta receptor (LTβR) and the tumor necrosis factor receptor 1 (TNFR1). Upon binding, it triggers a cascade of intracellular signaling pathways that can lead to cell death (apoptosis), cell survival, or inflammation, depending on the cellular context.
Biological Role[edit | edit source]
Tengonermin is involved in the development and organization of secondary lymphoid organs, such as lymph nodes and Peyer's patches. It plays a role in the maintenance of the architecture of these organs and in the regulation of immune responses.
In addition to its role in normal immune function, Tengonermin has been implicated in various pathological conditions, including autoimmune diseases, chronic inflammation, and cancer. Its ability to induce cell death makes it a potential target for cancer therapy, as it can selectively kill tumor cells.
Clinical Applications[edit | edit source]
Research into the therapeutic applications of Tengonermin is ongoing. Its potential use in cancer therapy is of particular interest, as it may enhance the immune system's ability to target and destroy cancer cells. However, the systemic administration of Tengonermin can lead to significant side effects, such as cytokine release syndrome, which limits its clinical use.
Research and Development[edit | edit source]
Studies are being conducted to better understand the mechanisms of Tengonermin action and to develop strategies to harness its therapeutic potential while minimizing adverse effects. This includes the development of targeted delivery systems and combination therapies with other immunomodulatory agents.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
